OBJECTIVES: Treatment outcome in children with acute myeloid leukemia (AML) has improved in the developed world but remains poor in developing countries. We assessed the role of etoposide in induction chemotherapy in pediatric AML. METHODS: This analysis retrospectively compared 2 induction chemotherapy regimens consisting of daunorubicin and cytarabine with etoposide (ADE) and without etoposide (AD). All newly diagnosed cases of AML younger than 18 years from January 1, 2012, onwards who completed their treatment before January 31, 2019, were included. Data of 186 cases, including 117 males (62.9%) and 69 females (37.1%), were analyzed. Demographic, initial presentation blood counts, and AML subtypes were almost identical in both groups. RESULTS: Complete remission rates were almost identical for the ADE versus the AD group (78.8% vs 80.0%, p = 0.980). Treatment-related mortality was higher, albeit not significantly, in the ADE (25 of 105; 23.8%) versus the AD (16 of 81; 19.8%) group (p = 0.508). Overall survival was 32 of 105 (30.5%) in the ADE and 43 of 81 (53.1%) in the AD group (p = 0.079), and disease-free survival was 29 of 105 (27.6%) and 39 of 81 (48.1%) in ADE and AD groups (p = 0.056), respectively. CONCLUSIONS: Etoposide in induction treatment of pediatric AML is associated with increased episodes of bacterial and fungal infections and high treatment-related mortality. Moreover, it does not offer any survival benefit. In low- and middle-income countries like Pakistan, it should not be used in the induction treatment protocol. Copyright Pediatric Pharmacy Association. All rights reserved. For permissions, email: mhelms@pediatricpharmacy.org 2020.
OBJECTIVES: Treatment outcome in children with acute myeloid leukemia (AML) has improved in the developed world but remains poor in developing countries. We assessed the role of etoposide in induction chemotherapy in pediatric AML. METHODS: This analysis retrospectively compared 2 induction chemotherapy regimens consisting of daunorubicin and cytarabine with etoposide (ADE) and without etoposide (AD). All newly diagnosed cases of AML younger than 18 years from January 1, 2012, onwards who completed their treatment before January 31, 2019, were included. Data of 186 cases, including 117 males (62.9%) and 69 females (37.1%), were analyzed. Demographic, initial presentation blood counts, and AML subtypes were almost identical in both groups. RESULTS: Complete remission rates were almost identical for the ADE versus the AD group (78.8% vs 80.0%, p = 0.980). Treatment-related mortality was higher, albeit not significantly, in the ADE (25 of 105; 23.8%) versus the AD (16 of 81; 19.8%) group (p = 0.508). Overall survival was 32 of 105 (30.5%) in the ADE and 43 of 81 (53.1%) in the AD group (p = 0.079), and disease-free survival was 29 of 105 (27.6%) and 39 of 81 (48.1%) in ADE and AD groups (p = 0.056), respectively. CONCLUSIONS:Etoposide in induction treatment of pediatric AML is associated with increased episodes of bacterial and fungal infections and high treatment-related mortality. Moreover, it does not offer any survival benefit. In low- and middle-income countries like Pakistan, it should not be used in the induction treatment protocol. Copyright Pediatric Pharmacy Association. All rights reserved. For permissions, email: mhelms@pediatricpharmacy.org 2020.
Authors: E FREI; J F HOLLAND; M A SCHNEIDERMAN; D PINKEL; G SELKIRK; E J FREIREICH; R T SILVER; G L GOLD; W REGELSON Journal: Blood Date: 1958-12 Impact factor: 22.113
Authors: J F Bishop; R M Lowenthal; D Joshua; J P Matthews; D Todd; R Cobcroft; M G Whiteside; H Kronenberg; D Ma; A Dodds Journal: Blood Date: 1990-01-01 Impact factor: 22.113
Authors: S Miyawaki; M Tanimoto; T Kobayashi; S Minami; J Tamura; E Omoto; K Kuriyama; K Hatake; K Saito; A Kanamaru; H Oh; S Ohtake; N Asou; H Sakamaki; O Yamada; I Jinnai; K Tsubaki; K Takeyama; A Hiraoka; S Matsuda; M Takahashi; C Shimazaki; K Adachi; S Kageyama; R Ohno Journal: Int J Hematol Date: 1999-08 Impact factor: 2.490
Authors: Thomas B Alexander; Lei Wang; Hiroto Inaba; Brandon M Triplett; Stanley Pounds; Raul C Ribeiro; Ching-Hon Pui; Jeffrey E Rubnitz Journal: Cancer Date: 2017-05-30 Impact factor: 6.860